farnesol has been researched along with Liver Neoplasms in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (15.38) | 18.2507 |
2000's | 2 (15.38) | 29.6817 |
2010's | 6 (46.15) | 24.3611 |
2020's | 3 (23.08) | 2.80 |
Authors | Studies |
---|---|
Balaraman, G; Krishnan, P; Mari, A; Salam, S; Sirajduddin, I; Subramaniam, N; Sundaram, J; Thiruvengadam, D | 1 |
Khuda-Bukhsh, AR; Mondal, J | 1 |
Chen, Y; Cheng, W; Dong, J; Jing, H; Liang, X; Liu, J; Shang, H; Wang, C; Wang, D; Wu, B; Yuan, Y; Zhou, Y | 1 |
Chen, T; Pang, Y; Qin, G; Wang, X; Wu, L; Wu, S; Xi, G | 1 |
Abarca, J; Borbath, I; Charette, N; De Saeger, C; Horsmans, Y; Leclercq, I; Schneider-Merck, T; Stärkel, P | 1 |
Charette, N; De Saeger, C; Horsmans, Y; Lannoy, V; Leclercq, I; Stärkel, P | 1 |
Ji, H; Lai, Y; Ling, Y; Peng, S; Tian, J; Ye, X; Zhang, Y; Zhang, Z | 1 |
Borbath, I; Stärkel, P | 1 |
Ji, H; Ling, Y; Tang, J; Yang, L; Zhang, Y; Zhang, Z; Zhao, Q | 1 |
Charette, N; De Saeger, C; Horsmans, Y; Leclercq, I; Stärkel, P | 1 |
Dagli, ML; de Conti, A; Heidor, R; Moreno, FS; Ong, TP | 1 |
Crick, DC; Feller, DR; Henry, KW; Noonan, DJ; O'Brien, ML; Rangwala, SM; Waechter, CJ; Weinberger, C | 1 |
Noonan, DJ; O'Brien, ML | 1 |
1 review(s) available for farnesol and Liver Neoplasms
Article | Year |
---|---|
A hypothetical mechanism for fat-induced rodent hepatocarcinogenesis.
Topics: Animals; DNA-Binding Proteins; Farnesol; Fats; Humans; Liver Neoplasms; Oxidative Stress; Receptors, Cytoplasmic and Nuclear; Rodentia; Transcription Factors | 1997 |
12 other study(ies) available for farnesol and Liver Neoplasms
Article | Year |
---|---|
Farnesol alleviates diethyl nitrosamine induced inflammation and protects experimental rat hepatocellular carcinoma.
Topics: Animals; Antioxidants; Carcinoma, Hepatocellular; Diethylnitrosamine; Farnesol; Inflammation; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Oxidative Stress; Rats; Rats, Wistar | 2021 |
Cisplatin and farnesol co-encapsulated PLGA nano-particles demonstrate enhanced anti-cancer potential against hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Drug Synergism; Farnesol; Humans; Liver Neoplasms; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Reactive Oxygen Species | 2020 |
Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Diathermy; Disease Models, Animal; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; ras Proteins; Salicylates; Sequence Analysis, RNA | 2021 |
Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Artemisinins; Carcinoma, Hepatocellular; Drug Synergism; Farnesol; Hep G2 Cells; Humans; Liver Neoplasms; Salicylates | 2017 |
The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Blotting, Western; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Diethylnitrosamine; Farnesol; Gene Expression Regulation, Neoplastic; Genes, ras; Hepatocytes; Immunohistochemistry; Liver Neoplasms; Male; Models, Animal; Rats; Rats, Wistar; Salicylates | 2009 |
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Farnesol; Female; Hep G2 Cells; Humans; Inhibitor of Apoptosis Proteins; Insulin-Like Growth Factor II; Liver Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; Salicylates; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitric Oxide Donors; Oxadiazoles; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Salicylates; Stereoisomerism; Structure-Activity Relationship; Toxicity Tests, Acute; Transplantation, Heterologous | 2011 |
Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Farnesol; Humans; Hypoglycemic Agents; Liver Neoplasms; Peptides, Cyclic; Pioglitazone; Salicylates; Somatostatin; Thiazolidinediones | 2011 |
ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Enzyme Activation; Farnesol; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred ICR; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Nitric Oxide; Oxadiazoles; Salicylates | 2011 |
Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase 8; Caspase 9; Cell Line, Tumor; Farnesol; Hep G2 Cells; Hepatocytes; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mitochondria; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Salicylates; Survivin; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase.
Topics: Acyclic Monoterpenes; Animals; Anticarcinogenic Agents; Apoptosis; Cell Proliferation; Cholesterol; Comet Assay; DNA Damage; Farnesol; Hepatocytes; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Male; Rats; Rats, Wistar; Terpenes | 2006 |
Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis.
Topics: Acyl-CoA Oxidase; Animals; Anticholesteremic Agents; Cholesterol; Farnesol; Fatty Acids, Unsaturated; Liver Neoplasms; Lovastatin; Microbodies; Oxidoreductases; Polyisoprenyl Phosphates; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Sesquiterpenes; Transcription Factors | 1996 |